

Validation & Assay Performance Summary



LanthaScreen™ STAT5 TF-1

Cat. no. K1598

Modification Detected: Phosphorylation of Tyr694/Tyr699

LanthaScreen Cellular Kinase Assay Validation Packet

This cell-based assay has been thoroughly tested and validated by Invitrogen and is suitable for immediate use in a screening application. The following information illustrates the high level of assay testing completed and the validation of assay performance under optimized conditions.

Pathway / Assay Description

In hematopoietic cells, the JAK2/STAT5 signaling pathway plays an essential role in blood cell formation in response to cytokines such as GM-CSF, IL-3, and EPO. In this pathway, binding of these cytokines to their respective cell surface receptors results in the activation of JAK2, which in turn phospho-activates STAT5 proteins at specific tyrosine residues (Tyr-694/699). LanthaScreen™-STAT5 TF-1 is a human hematopoietic cell line which constitutively expresses GFP-STAT5 fusion proteins. The JAK2/STAT5 signaling pathway is known to be functionally intact in this cell line, therefore the GFP-STAT5 fusion protein serves as a substrate for the inducible phosphorylation by JAK2. Using this cell line, a homogenous immuno-assay has been developed in which the phosphorylation state of GFP-STAT5 is detected in cell lysates using a LanthaScreen™ Terbium-anti-mouse and anti-phospho STAT5 [pTyr694/699] antibody pair, in a time-resolved FRET (TR-FRET) readout.

GFP-STAT5 α Lentivirus was transduced into TF-1 cells followed by selection with Blasticidine. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker, and has been screened for the constitutive expression of GFP-STAT5 fusion protein. Using a lytic TR-FRET immuno-assay, this cell line is validated for EC₅₀ and Z' under optimized conditions using GM-CSF as an agonist for JAK2-mediated GFP-STAT5 phosphorylation. This assay has also been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and lysis/equilibration time.

Validation Summary

Testing and validation of this assay was evaluated in a 384-well format using the LanthaScreen™ Tb-anti-mouse / anti-phospho STAT5 [Tyr 694/699] antibody pair.

1. Primary antagonist dose response under optimized conditions (Average of 3 experiments)

Z'-Factor (EC₁₀₀) = 0.64
Relative Response Ratio = 2.5x
EC₅₀ GM-CSF = 0.33 ng/mL

Recommended cell no. cells/well = 1x10⁵
Recommended [DMSO] = 0.1%
Recommended Stim. Time = 30 minutes
Recom. Assay incubation = 2 hours
Max. [Stimulation] = ~5 ng/mL

2. Cell culture and maintenance

See Cell Culture and Maintenance Section and Table 1

Assay Testing Summary

3. Assay performance with variable cell number

4. Assay performance with variable stimulation time

5. Assay performance with variable DMSO concentration


6. Assay performance with variable cell lysis/equilibration time

7. Assay performance with Alternate Agonist

8. Assay performance with small molecule inhibitor

Validation Experiments (3 Separate Days)

Figure 1 — GM-CSF-stimulated GFP-STAT5 phosphorylation in LanthaScreen™-STAT5 TF-1 cells under optimized conditions



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved in assay medium overnight in Petri dishes. On the day of the experiment, cells were plated at 100000 cells/well in 16 µL of assay medium, 384-well format. Cells were then pretreated with 2 µL of assay medium containing 1% DMSO before treatment with the indicated concentration of GM-CSF (2 µL addition) for 30 minutes. Cells were lysed by addition of 15 µL lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and incubated for 120 min at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 8 replicates at each data point.

Cell Culture and Maintenance

Thaw cells in Growth Medium without Blastidicin and culture them in Growth Medium with Blastidicin. These cells are dependent on 2 ng/mL GM-CSF for growth, and this reagent should be added at time of passage. Pass or feed cells at least twice a week and maintain them in a

37°C/5% CO₂ incubator. Maintain cells between 5x10⁴ and 1x10⁶/mL. Do not allow cells to exceed 1x10⁶/mL.


Note: We recommend passing cells for three passages after thawing before using them in the LanthaScreen™ assay. For more detailed cell growth and maintenance directions, please refer to the protocol.

Table 1 – Cell Culture and Maintenance

Component	Growth Medium	Assay Medium	Freezing Medium
RPMI 1640	90%	—	—
Opti-MEM I®	—	99%	—
Dialyzed FBS Do Not Substitute!	10%	--	—
Charcoal/Dextran-Treated FCS	--	0.5%	—
NEAA	0.1 mM	0.1 mM	—
Sodium pyruvate	1 mM	1 mM	—
GM-CSF	2 ng/mL	--	--
Penicillin (antibiotic)	100 U/mL	100 U/mL	—
Streptomycin (antibiotic)	100 µg/mL	100 µg/mL	—
Blasticidin (antibiotic)	5 µg/mL	—	—
Recovery™ Cell Culture Freezing Medium	—	—	100%

Assay Performance with Variable Cell Number


Figure 2 — GM-CSF-stimulated GFP-STAT5 phosphorylation in LanthaScreen™-STAT5 TF-1 cells under variable cell plating density



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved overnight in assay medium in Petri dishes. On the day of the experiment, cells were plated at the indicated cells/well in assay medium, 384-well format. Cells were then stimulated with the indicated concentration of GM-CSF (to 20 μ L total volume) for 30 minutes. Cells were lysed by addition of 15 μ L lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and incubated for 120 min at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 3 replicates at each data point.

Assay Performance with Variable Stimulation Time


Figure 3 — GM-CSF-stimulated GFP-STAT5 phosphorylation in LanthaScreen™-STAT5 TF-1 cells under variable stimulation times.



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved overnight in assay medium in Petri dishes. On the day of the experiment, cells were plated at 100000 cells/well in assay medium, 384-well format. Cells were then treated with the indicated concentration of GM-CSF (to 20 μ L total volume) for the time indicated. Cells were lysed by addition of 15 μ L lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and incubated for 120 min at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 3 replicates at each data point.

Assay Performance with Variable DMSO Concentration


Figure 4 – GM-CSF-stimulated GFP-STAT5 phosphorylation in LanthaScreen™-STAT5 TF-1 cells with variable DMSO concentrations



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved overnight in assay medium in Petri dishes. On the day of the experiment, cells were plated at 100000 cells/well in assay medium, 384-well format. Cells were pretreated with the indicated concentration of DMSO before stimulation with GM-CSF (to 20 μ L total volume) for 30 minutes. Cells were lysed by addition of 15 μ l lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and incubated for 120 min at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 3 replicates at each data point.

Assay Performance with Variable Assay Equilibration Time



Figure 5 — GM-CSF-stimulated GFP-STAT5 phosphorylation in LanthaScreen™-STAT5 TF-1 cells under variable lysis/equilibration times



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved overnight in assay medium in Petri dishes. On the day of the experiment, cells were plated at 100000 cells/well in assay medium, 384-well format. Cells were then treated with the indicated concentration of GM-CSF (to 20 μ L total volume) for 30 minutes. Cells were lysed by addition of 15 μ l lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and allowed to equilibrate for the time indicated at room temperature before being measured. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 3 replicates at each data point.

Assay Performance with Alternate Agonist


Figure 6 —IL3/EPO-stimulated GFP-STAT5 phosphorylation in LanthaScreen™-STAT5 TF-1 cells.



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved overnight in assay medium in Petri dishes. On the day of the experiment, cells were plated at 100000 cells/well in assay medium, 384-well format. Cells were then treated with the indicated concentration of IL-3 or EPO (to 20 μ L total volume) for the 30 minutes. Cells were lysed by addition of 15 μ L lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and incubated for 120 min at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 3 replicates at each data point.

Assay Performance with Small Molecule Inhibitor

Figure 7 — Inhibition of JAK-mediated phosphorylation in LanthaScreen™-STAT5 TF-1 cells.



On the day prior to the assay, LanthaScreen™-STAT5 TF-1 were starved overnight in assay medium in Petri dishes. On the day of the experiment, cells were plated at 100000 cells/well in assay medium, 384-well format. Cells were pretreated with the indicated concentration of JAK Inhibitor I before stimulation with 2.5 ng/mL GM-CSF (to 20 μ L total volume) for 30 minutes. Cells were lysed by addition of 15 μ L lysis buffer, which included 5 nM anti-phospho-STAT5 [pTyr 694/699] + 10 nM LanthaScreen™ Tb-anti-mouse antibodies, and incubated for 120 min at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG Pherastar plate reader set to TR-FRET mode. The 520/490 nm Emission Ratios are plotted for each experiment, and are represented by the average of at least 3 replicates at each data point.